Patents Assigned to GALECTO BIOTECH AB
  • GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20210380624
    Abstract: A compound of the general formula I or II. The compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 9, 2021
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Ulf NILSSON, Thomas BRIMERT, Kristoffer PETERSON, Karl JANSSON
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20210284678
    Abstract: An ?-D-galactopyranose compound of the general formula (1). The ?-D-galactopyranose compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: May 24, 2021
    Publication date: September 16, 2021
    Applicant: GALECTO BIOTECH AB
    Inventor: Fredrik ZETTERBERG
  • IDIOPATHIC PULMONARY FIBROSIS-DETECTION, MONITORING, PREDICTION METHODS
    Publication number: 20210221836
    Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.
    Type: Application
    Filed: April 2, 2021
    Publication date: July 22, 2021
    Applicant: GALECTO BIOTECH AB
    Inventors: Neil HENDERSON, Tariq SETHI, Alison MACKINNON, Hakon LEFFLER, Ulf NILSSON
  • Galactoside inhibitor of galectins
    Patent number: 11046725
    Abstract: An ?-D-galactopyranose compound of the general formula (1). The ?-D-galactopyranose compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: June 29, 2021
    Assignee: GALECTO BIOTECH AB
    Inventor: Fredrik Zetterberg
  • Alpha-D-galactoside inhibitors of galectins
    Patent number: 10988502
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: July 9, 2017
    Date of Patent: April 27, 2021
    Assignee: GALECTO BIOTECH AB
    Inventors: Fredrik Zetterberg, Hakon Leffler, Ulf Nilsson
  • Alpha-D-galactoside inhibitors of galectins
    Patent number: 10889610
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: July 9, 2017
    Date of Patent: January 12, 2021
    Assignee: GALECTO BIOTECH AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20200407391
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20200347089
    Abstract: An ?-D-galactopyranose compound of the general formula (1). The ?-D-galactopyranose compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: January 9, 2019
    Publication date: November 5, 2020
    Applicant: GALECTO BIOTECH AB
    Inventor: Fredrik ZETTERBERG
  • Polymorphic forms and process
    Patent number: 10799482
    Abstract: A process for preparing an amorphous form of a compound of formula (I) This amorphous compound I is particularly suitable in treating IPF by pulmonary administration.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: October 13, 2020
    Assignee: GALECTO BIOTECH AB
    Inventors: Lise Gravelle, Anders Pedersen
  • Galactoside inhibitor of galectins
    Patent number: 10774102
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 15, 2020
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • 1,1 ?-sulfanediyl-di-beta-D-galactopyranosides as inhibitors of galectins
    Patent number: 10730902
    Abstract: The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: August 4, 2020
    Assignee: GALECTO BIOTECH AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler, Anders Pedersen, Hans Schambye, Thomas Brimert, Richard Johnsson
  • Galactoside inhibitor of galectins
    Patent number: 10526360
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: January 7, 2020
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • IDIOPATHIC PULMONARY FIBROSIS-DETECTION, MONITORING, PREDICTION METHODS
    Publication number: 20190375776
    Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.
    Type: Application
    Filed: August 5, 2019
    Publication date: December 12, 2019
    Applicant: GALECTO BIOTECH AB
    Inventors: Neil Henderson, Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20190359643
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: August 13, 2019
    Publication date: November 28, 2019
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • Galactoside inhibitor of galectins
    Patent number: 10464964
    Abstract: An Embodiment of the invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: November 5, 2019
    Assignee: Galecto Biotech AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler, Thomas Brimert, Richard Johnsson, Priya Verma
  • ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20190315793
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: July 9, 2017
    Publication date: October 17, 2019
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Ulf NILSSON, Hakon LEFFLER
  • POLYMORPHIC FORMS AND PROCESS
    Publication number: 20190298697
    Abstract: A process for preparing an amorphous form of a compound of formula (I) This amorphous compound I is particularly suitable in treating IPF by pulmonary administration.
    Type: Application
    Filed: May 13, 2019
    Publication date: October 3, 2019
    Applicant: GALECTO BIOTECH AB
    Inventors: Lise GRAVELLE, Anders PEDERSEN
  • Polymorphic forms and process
    Patent number: 10369136
    Abstract: The present invention relates to a polymorph of a compound of formula (I) This polymorph is particularly suitable in treating IPF by pulmonary administration.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: August 6, 2019
    Assignee: GALECTO BIOTECH AB
    Inventors: Lise Gravelle, Anders Pedersen
  • ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20190225638
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: July 9, 2017
    Publication date: July 25, 2019
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Hakon LEFFLER, Ulf NILSSON
  • Polymorphic forms and process
    Patent number: 10307403
    Abstract: The present invention relates to a polymorph of a compound of formula (I) This polymorph is particularly suitable in treating IPF by pulmonary administration.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: June 4, 2019
    Assignee: GALECTO BIOTECH AB
    Inventors: Lise Gravelle, Anders Pedersen